Amgen Aktie News

Amgen (AMGN) shares surged more than 14% in extended-hours trading on Thursday after the biopharmaceutical giant posted quarterly earnings that came in ahead of Wall Street expectations and provided a positive update about trials of its injectable weight-loss drug MariTide.

Amgen, Inc. (NASDAQ:AMGN ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Research and Development & Chief Scientific Officer Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Murdo Gordon - EVP, Global Commercial Operations Peter Gri...

Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-loss drug are proceeding apace.

Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.

Amgen stock dipped late Thursday despite beating first-quarter expectations. The company is running a midstage study of its obesity drug.

THOUSAND OAKS, Calif. , May 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.

Here are three prominent Dow stocks facing challenges that every investor should be aware of. Even with any business's challenges, savvy investors can identify possible openings for strategic positioning.

American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and Nasdaq 100 indices fell by over 10 basis points.